

Related Change Request (CR) #: 2554

Medlearn Matters Number: MM2554

Related CR Release Date: August 12, 2003

Related CR Transmittal #: AB-03-130

Effective Date: January 1, 2003

Implementation Date: January 1, 2004


Levocarnitine for Use in the Treatment of Carnitine Deficiency in ESRD Patients

Provider Types Affected

Providers who bill for intravenous levocarnitine received by End Stage Renal Disease (ESRD) patients on or after January 1, 2003.

Provider Action Needed

Affected providers should be aware of these payment instructions for intravenous levocarnitine provided to End Stage Renal Disease (ESRD) patients on or after January 1, 2003. Although these changes were effective on January 1, 2003, they will be implemented in Medicare's claims processing systems on January 1, 2004.



STOP

Levocarnitine will be covered by Medicare only if certain coverage rules are met. All other indications for levocarnitine are non-covered in the ESRD population.

CAUTION

This article explains the coverage requirements for Medicare payment for levocarnitine.

GO

Be sure to follow these guidelines when billing for levocarnitine to assure accurate and prompt payments from Medicare for this drug.

Background

Initial Use The use of intravenous levocarnitine will only be covered for End Stage Renal Disease (ESRD) patients who have been on dialysis for a minimum of 3 months **and** must have documented carnitine deficiency (defined as a plasma free carnitine level <40 micromol/L) **and** signs and symptoms of:

1. Erythropoietin-resistant anemia (persistent hematocrit <30 percent with treatment) that has not responded to standard erythropoietin dosage (that which is considered clinically appropriate to treat the particular patient) with iron replacement, and for which other causes have been investigated and adequately treated; **or**

Disclaimer

Medlearn Matters articles are prepared as a service to the public and are not intended to grant rights or impose obligations. Medlearn Matters articles may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.

2. Hypotension on hemodialysis that interferes with delivery of the intended dialysis despite application of usual measures deemed appropriate (e.g., fluid management). Such episodes of hypotension must have occurred during at least 2 dialysis treatments in a 30-day period.

Continued use of levocarnitine will not be covered if improvement has not been demonstrated within 6 months of treatment.

All other indications for levocarnitine are non-covered in the ESRD population.

Continued Use For a patient currently receiving intravenous levocarnitine, Medicare will cover continued treatment if:

1. Levocarnitine has been administered to treat a) erythropoietin-resistant anemia or b) hypotension on hemodialysis, as described above, **and**
2. The patient's medical record documents a pre-dialysis plasma free carnitine level <40 micromol/L prior to the initiation of treatment; **or**
3. The treating physician certifies in the medical record that in his/her judgment, if treatment with levocarnitine is discontinued, the patient's pre-dialysis carnitine level would fall below 40 micromol/L and the patient would have recurrent erythropoietin-resistant-anemia or intradialytic hypotension.

Implementation

The implementation date is January 1, 2004, and the effective date of the change is January 1, 2003.

Related Instructions

Billing Requirements

For Claims Submitted to Intermediaries The applicable bill type: 72x (**Note:** A Free-standing ESRD Facility is reimbursed at 95% of AWP; Hospital-based ESRD Facility is reimbursed at cost (Deductible and coinsurance apply)).

When using the UB-92 flat file, use record type 40 for bill type. When using the hard copy UB-92 report, the applicable bill type is Form Locator (FL) 4 "Type of Bill."

For those using X12N 837 formats, the following is provided to assist in your implementation efforts: The Medicare A 837 Health Care Claim version 3051 implementations 3A.01 and 1A.C1 (Appendix C of both documents have UB-92 mapping), along with the UB-92 version 6.0 can be found at:

<http://www.cms.hhs.gov/providers/edi/edi3.asp>.

These formats were effective through October 16, 2003. The X12N 837 to UB-92 version 6.0 mapping is at:

<http://www.cms.hhs.gov/providers/edi/hipaadoc.asp>.

The HIPAA 837 can be downloaded from:

<http://www.wpc-edi.com>.

Disclaimer

Medlearn Matters articles are prepared as a service to the public and are not intended to grant rights or impose obligations. Medlearn Matters articles may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.

This drug should be billed on Form CMS-1450 (or electronic equivalent) under the revenue code 0636 along with HCPC J1955. When using the UB-92 flat file use record type 61 for the Revenue Code (Field No.5); for the HCPC, use Field No. 6. When using the hard copy UB-92, report revenue code in FL 42 "Revenue Code" and report the HCPC code in FL 44 "CPT/Rates."

For Claims Submitted to Carriers Follow the general instruction for preparing claims in **§2010 Medicare Carriers Manual (MCM) Part 4, Chapter 2, Purpose of Health Insurance Claim Form CMS-1500**. Submit claims for Levocarnitine on health insurance claim Form CMS-1500 or electronic equivalent. Claims should be processed in accordance with **§4020, MCM, Review of Health Insurance Claim Form CMS-1500, Part 3**.

Coinsurance and deductible apply.

If providers submit claims that do not meet one or more of the requirements described above, they will receive the following message on their remittance advice:

"6.5- Medicare cannot pay for this injection because one or more requirements for coverage were not met."

To view the actual Medicare transmittal for this issue, please visit:

http://www.cms.hhs.gov/manuals/pm_trans/AB03130.pdf.

Disclaimer

Medlearn Matters articles are prepared as a service to the public and are not intended to grant rights or impose obligations. Medlearn Matters articles may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.